Tirzepatide vs Semaglutide: Comparing the Two Most Powerful GLP-1 Therapies
Head-to-head comparison of tirzepatide and semaglutide. Mechanism differences, clinical trial results, side effect profiles, and which GLP-1 therapy may be right for you.
The GLP-1 Revolution
GLP-1 receptor agonists have transformed the landscape of metabolic medicine. Two compounds have emerged as the frontrunners: semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). While both target the GLP-1 receptor, their mechanisms, efficacy profiles, and clinical data differ in important ways.
Understanding these differences helps patients and physicians make informed decisions about which therapy best matches individual goals, health profiles, and tolerance patterns.
Mechanism of Action: Single vs Dual Agonist
Semaglutide is a pure GLP-1 receptor agonist. It activates GLP-1 receptors in the brain (reducing appetite), pancreas (improving insulin secretion), and gut (slowing gastric emptying). This single-target approach has proven highly effective.
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its kind. It activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. GIP has independent effects on fat metabolism, insulin sensitivity, and bone health that complement GLP-1 activity.
The dual mechanism produces a synergistic metabolic effect. GIP receptor activation in adipose tissue enhances fat oxidation and improves lipid handling, while the combined GLP-1/GIP signaling in the brain provides more robust appetite suppression than either pathway alone.
For comparison, Retatrutide — the next-generation triple agonist (GLP-1/GIP/glucagon) — adds glucagon receptor activation for even greater metabolic impact. Phase 2 trials showed up to 24% body weight reduction, suggesting that each additional receptor target amplifies the metabolic effect.
Clinical Trial Results: Head-to-Head Data
The SURMOUNT clinical trial program demonstrated tirzepatide's efficacy at its highest dose (15mg weekly): 22.5% average body weight reduction over 72 weeks. At the 10mg dose, average weight loss was 19.5%, and at 5mg it was 15%.
Semaglutide's STEP trials showed 16.9% average weight loss at 2.4mg over 68 weeks. The SELECT cardiovascular outcomes trial additionally demonstrated a 20% reduction in major adverse cardiovascular events (MACE).
The SURPASS-2 head-to-head trial compared tirzepatide directly against semaglutide 1mg (not the maximum 2.4mg weight management dose). All three tirzepatide doses (5mg, 10mg, 15mg) produced greater HbA1c reductions and weight loss than semaglutide 1mg.
Both compounds show remarkable improvements in metabolic biomarkers beyond weight loss: reduced triglycerides, improved liver enzymes (suggesting reduced hepatic fat), lower inflammatory markers, and improved insulin sensitivity. Tirzepatide may have a slight edge in lipid improvements due to GIP's effects on fat metabolism.
Side Effect Profiles and Tolerability
Both compounds share similar GI side effect profiles — nausea, diarrhea, vomiting, and constipation are the most common. However, the incidence and severity differ.
Tirzepatide appears to have slightly lower rates of nausea at comparable efficacy levels. Some researchers attribute this to the GIP component, which may buffer some of the GLP-1-mediated gut effects. In SURPASS trials, nausea rates ranged from 12-18% depending on dose.
Semaglutide nausea rates in STEP trials ranged from 20-44% depending on the study and dose. However, nausea was typically transient and most common during dose escalation. With proper titration, most patients tolerate both medications well.
Both compounds carry similar warnings regarding pancreatitis risk, gallbladder disease, and thyroid C-cell tumor risk (from rodent studies). Regular monitoring with metabolic panels and lipid profiles is recommended for both.
Which One Is Right for You?
The choice between tirzepatide and semaglutide depends on individual factors. Tirzepatide may be preferred when maximum weight loss is the primary goal, when a patient has significant insulin resistance or type 2 diabetes, or when GI tolerability is a concern.
Semaglutide may be preferred when cardiovascular risk reduction is a priority (based on SELECT trial data), when a well-established long-term safety profile is important, or when cost and insurance coverage are deciding factors.
Both compounds are available in our Dose Calculator with full titration schedules and reconstitution math. Explore the Compound Wiki at longevityai.io to compare all 100 compounds, or ask our AI advisor for personalized guidance on which GLP-1 therapy aligns with your goals.